We hypothesize that tumor-specific CD8+ T cell responses are largely derived from the periphery in NeoAg/ICB-based immunotherapies and can remain ignorant of CD4+ T cell specificity in a vaccine, as long as help is provided. The gene discussed is CD8A; the disease is neoplasm.